Home » Health » Cancer Immunotherapy Risks: Financial Authorities Urged to Intervene

Cancer Immunotherapy Risks: Financial Authorities Urged to Intervene

by Dr. Michael Lee – Health Editor

Financial ​Authorities Scrutinize⁢ Cancer Immunization Enhancement Claims Amid Rising Healthcare ⁢costs

SEOUL, SOUTH KOREA – South Korean⁣ financial authorities are increasing oversight of cancer immunization enhancement prescriptions and related insurance​ claims, citing ⁣concerns over possibly unnecessary treatments and escalating healthcare costs. The move comes as reports surface of medical​ institutions ‌allegedly exaggerating the benefits of‌ non-covered immunization enhancements,⁢ and in certain ‍specific cases, refusing hospitalization to patients who decline costly, unproven treatments.

The escalating situation ‌threatens to exacerbate already strained relationships between ⁢insurers and policyholders, particularly as loss‍ insurance rates ⁤continue to deteriorate. The third generation of⁢ loss insurance recorded a loss rate of‌ 155.3% in 2023, remaining around 150% in the first half of 2024. Newer, fourth-generation loss insurance is also experiencing rising loss rates, reaching 131.4% in⁣ the first ⁣half of last year. These figures highlight a growing financial burden on the insurance industry, prompting‍ calls for regulatory intervention.

Financial authorities recently instructed insurers to prioritize “consumer protection in terms⁢ of⁣ cancer immunization enhancement benefits,”​ signaling a proactive approach​ to address potential abuses.⁣ This guidance ⁤follows concerns that some medical facilities may be utilizing ‍U.S.-based⁣ medical ⁣technologies – frequently enough not fully covered by insurance ⁢- as ⁤a revenue source, potentially leading to unnecessary procedures.

The insurance industry has welcomed the administrative guidance,but is also advocating for revisions to standard loss insurance ​terms and conditions. ⁤An industry⁤ official stated that the lack of clarity​ surrounding the side effects and efficacy of these emerging medical technologies necessitates a comprehensive review. ⁤ ⁢”If medical institutions use US-based medical technology as a means of revenue, unnecessary treatment will increase and‍ construction insurance fiscal soundness⁣ will⁢ be deteriorated,” the official said, urging the authorities to retroactively examine existing policies.Hong Chang-ki, ThevyFirst@fnnews.com
Financial News – Unauthorized reproduction-No redistribution.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.